LU92545I2 - Ezetimibe en combinaison avec atorvastatine ou leurs sels pharmaceutiquement acceptées, y compris atorvastatine sous forme d'atorvastatine calcique trihydratée - Google Patents

Ezetimibe en combinaison avec atorvastatine ou leurs sels pharmaceutiquement acceptées, y compris atorvastatine sous forme d'atorvastatine calcique trihydratée Download PDF

Info

Publication number
LU92545I2
LU92545I2 LU92545C LU92545C LU92545I2 LU 92545 I2 LU92545 I2 LU 92545I2 LU 92545 C LU92545 C LU 92545C LU 92545 C LU92545 C LU 92545C LU 92545 I2 LU92545 I2 LU 92545I2
Authority
LU
Luxembourg
Prior art keywords
atorvastatin
aryl
alkyl
substd
ezetimibe
Prior art date
Application number
LU92545C
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92545(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of LU92545I2 publication Critical patent/LU92545I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Dental Preparations (AREA)
  • Pyrane Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU92545C 1993-09-21 2014-09-12 Ezetimibe en combinaison avec atorvastatine ou leurs sels pharmaceutiquement acceptées, y compris atorvastatine sous forme d'atorvastatine calcique trihydratée LU92545I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10244093A 1993-09-21 1993-09-21
US08/257,593 US5631365A (en) 1993-09-21 1994-06-09 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
PCT/US1994/010099 WO1995008532A1 (fr) 1993-09-21 1994-09-14 Composes d'azetidinone hydroxy-substitues efficaces en tant qu'agents hypocholesterolemiques

Publications (1)

Publication Number Publication Date
LU92545I2 true LU92545I2 (fr) 2015-09-21

Family

ID=26799377

Family Applications (4)

Application Number Title Priority Date Filing Date
LU91050C LU91050I2 (fr) 1993-09-21 2003-12-12 Composes d'azetidinone hydroxy-substitues efficaces en tant qu'agents hypocholesterolemiques.
LU91160C LU91160I2 (fr) 1993-09-21 2005-04-01 Ezetimible ou ses sels acceptés en combinaison avec Simvastatin (Inegy/Vytorin).
LU92544C LU92544I2 (fr) 1993-09-21 2014-09-11 Ezetimibe en combinaison avec rosuvastatine ou luers sels pharmaceutiquement acceptées, y compris rosuvastatine sous forme de sel de zinc
LU92545C LU92545I2 (fr) 1993-09-21 2014-09-12 Ezetimibe en combinaison avec atorvastatine ou leurs sels pharmaceutiquement acceptées, y compris atorvastatine sous forme d'atorvastatine calcique trihydratée

Family Applications Before (3)

Application Number Title Priority Date Filing Date
LU91050C LU91050I2 (fr) 1993-09-21 2003-12-12 Composes d'azetidinone hydroxy-substitues efficaces en tant qu'agents hypocholesterolemiques.
LU91160C LU91160I2 (fr) 1993-09-21 2005-04-01 Ezetimible ou ses sels acceptés en combinaison avec Simvastatin (Inegy/Vytorin).
LU92544C LU92544I2 (fr) 1993-09-21 2014-09-11 Ezetimibe en combinaison avec rosuvastatine ou luers sels pharmaceutiquement acceptées, y compris rosuvastatine sous forme de sel de zinc

Country Status (35)

Country Link
US (5) US5631365A (fr)
EP (1) EP0720599B1 (fr)
JP (1) JP2803908B2 (fr)
KR (1) KR100186853B1 (fr)
CN (1) CN1050830C (fr)
AT (1) ATE180249T1 (fr)
AU (1) AU681445C (fr)
BE (1) BE2014C056I2 (fr)
BR (1) BR1100159A (fr)
CA (1) CA2172149C (fr)
CZ (2) CZ288861B6 (fr)
DE (3) DE122004000026I2 (fr)
DK (1) DK0720599T3 (fr)
ES (1) ES2132432T3 (fr)
FI (1) FI110321B (fr)
FR (2) FR05C0040I2 (fr)
GE (1) GEP20043149B (fr)
GR (1) GR3030312T3 (fr)
HU (1) HU221185B1 (fr)
IL (1) IL110956A (fr)
LU (4) LU91050I2 (fr)
MA (1) MA23332A1 (fr)
MY (1) MY111314A (fr)
NL (2) NL300132I2 (fr)
NO (6) NO305902B1 (fr)
NZ (1) NZ274041A (fr)
PL (1) PL182617B1 (fr)
RU (1) RU2138480C1 (fr)
SG (1) SG46208A1 (fr)
SK (1) SK281067B6 (fr)
TN (1) TNSN94094A1 (fr)
TW (1) TW427974B (fr)
UA (1) UA41948C2 (fr)
WO (1) WO1995008532A1 (fr)
ZA (1) ZA947086B (fr)

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CA2191455A1 (fr) * 1994-06-20 1995-12-28 Wayne Vaccaro Composes d'azetidinone substitues utilises comme agent hypercholesterolemiant
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
AU7361796A (en) * 1995-09-27 1997-04-17 Schering Corporation Stereoselective microbial reduction process
EP0766962A3 (fr) * 1995-10-03 2000-05-10 Beiersdorf-Lilly GmbH Traitement de l'athérosclérose
US5843938A (en) * 1995-10-03 1998-12-01 Beiersdorf-Lilly Gmbh Treatment of atherosclerosis
CZ293957B6 (cs) * 1995-10-31 2004-08-18 Scheringácorporation @@Azetidinony substituované cukernými zbytkyŹ použitelné jako hypocholesterolemikaŹ farmaceutický prostředek a kit je obsahující
WO1997016424A1 (fr) * 1995-11-02 1997-05-09 Schering Corporation Procede de preparation de 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl ou 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
JP4212112B2 (ja) 1996-02-23 2009-01-21 イーライ・リリー・アンド・カンパニー 非ペプチジルバソプレッシンＶ１ａアンタゴニスト
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2762336B1 (fr) * 1997-04-21 1999-06-11 Francois Trantoul Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
CA2353981C (fr) * 1998-12-07 2005-04-26 Schering Corporation Procede relatif a la synthese d'azetidinones
CA2356157C (fr) * 1998-12-23 2008-04-01 G.D. Searle Llc Combinaisons d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle et de derives de l'acide fibrique utilisees dans le cadre de troubles cardio-vasculaires
EP1140185B1 (fr) 1998-12-23 2003-06-04 G.D. Searle LLC. Combinaisons d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle et d'agents sequestrants de l'acide biliaire, utilisees dans le cadre de toubles cardio-vasculaires
EA004877B1 (ru) * 1998-12-23 2004-08-26 Джи.Ди.Сирл Ллс Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
ATE242007T1 (de) * 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
EP1354604A1 (fr) * 1998-12-23 2003-10-22 G.D. Searle LLC. Combinaisons pour indications cardiovasculaires
AU776620B2 (en) 1998-12-23 2004-09-16 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
ATE240120T1 (de) 1998-12-23 2003-05-15 Searle Llc Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
CA2367289C (fr) 1999-04-05 2008-02-12 Schering Corporation Reduction microbienne stereoselective permettant de preparer 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU2001240115A1 (en) 2000-03-10 2001-09-24 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
WO2002036124A2 (fr) * 2000-10-30 2002-05-10 Schering Corporation Procede de traitement
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1593670B1 (fr) * 2000-12-20 2007-08-08 Schering Corporation 2-Azétidinones substitués par hydroxy utilisés comme hypocholestérolémiants
ATE369334T1 (de) * 2000-12-20 2007-08-15 Schering Corp Hydroxysubstituierte 2-azetidinone verwendbar als hypocholesterolemische arzneimittel
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1510521A1 (fr) * 2000-12-20 2005-03-02 Schering Corporation 2-azetidinones substitués par le sucre utilisés comme agents hypocholestérolémiants
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
BR0116325A (pt) * 2000-12-21 2003-10-14 Aventis Pharma Gmbh 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
DE10064402A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10064398A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AU2006203175B2 (en) * 2001-01-26 2008-07-24 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
SI1363668T1 (sl) * 2001-01-26 2007-12-31 Schering Corp Kombinacija sekvestranta(-ov) in zaviralca(-ev) absorpcije sterola ter zdravljenje vaskularnih indikacij
AU2007201970B2 (en) * 2001-01-26 2008-04-17 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20020147184A1 (en) * 2001-01-26 2002-10-10 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
CN1582168A (zh) * 2001-01-26 2005-02-16 先灵公司 用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合
RS20100015A (sr) * 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
AU2006202618B2 (en) * 2001-01-26 2007-04-19 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1911462A3 (fr) 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
AU2002240050A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
AU2008201609B8 (en) * 2001-01-26 2009-01-08 Organon Llc Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
HU230435B1 (hu) * 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
US6627757B2 (en) 2001-03-28 2003-09-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
MXPA03010843A (es) * 2001-05-25 2004-02-17 Schering Corp Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer.
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
CA2460340C (fr) 2001-09-21 2011-02-15 Schering Corporation Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
SI1429756T1 (sl) * 2001-09-21 2007-02-28 Schering Corp Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2003040127A1 (fr) * 2001-11-02 2003-05-15 G.D. Searle Llc Composes benzothiepine mono- et di-fluores en tant qu'inhibiteurs du transport d'acides biliaires a co-dependance sodique apicale (asbt) et de reprise de taurocholate
JP2006506314A (ja) * 2001-11-09 2006-02-23 アセロジエニクス・インコーポレイテツド 心血管疾患の逆転及び予防方法
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
JP2005516941A (ja) * 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
CA2471639A1 (fr) 2002-01-17 2003-07-31 Pharmacia Corporation Nouveaux composes d'alkyl/aryl hydroxy ou cetothiepine servant d'inhibiteurs du transport des acides biliaires de type ileal et de l'absorption de taurocholate
AU2003217276A1 (en) * 2002-02-28 2003-09-16 Eli Lilly And Company Method of treating atherosclerosis and hypercholesterolemia
US20040116510A1 (en) * 2002-03-05 2004-06-17 Nichtberger Steven A. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
EP1656368A4 (fr) 2002-07-09 2009-08-26 Bristol Myers Squibb Co Derives heterocycliqes substitues utiles comme agents antidiabetique et antiabesite et leur procede de fabrication
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
DE60334711D1 (de) 2002-07-30 2010-12-09 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
WO2004056727A2 (fr) * 2002-12-19 2004-07-08 Atherogenics, Inc. Procede de fabrication de derives de chalcone
CA2517571C (fr) 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
EP1626954A2 (fr) * 2003-05-05 2006-02-22 Ranbaxy Laboratories, Ltd. Procede pour la preparation de trans-isomeres de derives de diphenylazetidinone
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
BRPI0410840A (pt) * 2003-05-30 2006-07-04 Ranbaxy Lab Ltd derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
EP1635813A4 (fr) * 2003-06-06 2009-07-01 Merck & Co Inc Polytherapie permettant de traiter la dyslipidemie
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
JP2006528630A (ja) * 2003-07-24 2006-12-21 メルク　エンド　カムパニー　インコーポレーテッド ジフェニル置換シクロアルカン類、そのような化合物を含む組成物、ならびに使用方法
WO2005009955A1 (fr) * 2003-07-31 2005-02-03 Hetero Drugs Limited Polymorphes de l'ezetimibe
EP1522541A1 (fr) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Nouveaux composés hypocholesterolémiques
WO2005042692A2 (fr) * 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. Methode permettant d'inhiber l'expression de genes qui induisent l'influx de cholesterol cellulaire dans les cellules animales et d'inhiber la production de proteines issues de l'expression de ces genes
EP1680189A2 (fr) * 2003-11-05 2006-07-19 Schering Corporation Combinaisons de modulateurs lipidiques et d'azetidinones substituees et traitements d'affections vasculaires
EP1918000A2 (fr) 2003-11-05 2008-05-07 Schering Corporation Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
EP1682499B1 (fr) * 2003-11-10 2007-08-08 Microbia, Inc. 4-biarylyl-1-ph nylaz tidin-2-ones
EP1687287A1 (fr) * 2003-11-24 2006-08-09 Hetero Drugs Limited Nouveau procede de preparation d'intermediaire d'ezetimibe
WO2005061452A1 (fr) * 2003-12-23 2005-07-07 Astrazeneca Ab Derives diphenylazetidinone a activite inhibitrice de l'absorption du cholesterol
WO2005062824A2 (fr) 2003-12-23 2005-07-14 Merck & Co., Inc. Composes anti-hypercholesterolemie
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005069900A2 (fr) * 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) et procédés pour identifier des ligands de ceux-ci
DK1725234T4 (en) * 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
WO2005113496A1 (fr) * 2004-05-21 2005-12-01 Sanofi-Aventis Deutschland Gmbh Procede pour produire des derives de 1,4-diphenylazetidinone
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006004903A2 (fr) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(phenyl-substitue)-2-propen-1-ones et des compositions pharmaceutiques en contenant
US20070244107A1 (en) * 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
AR050631A1 (es) * 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
EP1834180A2 (fr) * 2004-12-15 2007-09-19 Schering Corporation Essais fonctionnels pour l'identification d'inhibiteurs d'absorption du cholesterol
US20130082232A1 (en) 2011-09-30 2013-04-04 Unity Semiconductor Corporation Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
WO2006107936A1 (fr) * 2005-04-04 2006-10-12 Pontificia Universidad Catolica De Chile Utilisation d'ezetimibe pour prevenir et traiter des calculs biliaires de cholesterol
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
CA2608108A1 (fr) * 2005-05-09 2006-11-16 Microbia, Inc. Agents de couplage de benzenephosphonate organometallique
BRPI0608970A2 (pt) * 2005-05-11 2010-02-17 Microbia Inc processos para produção de 4-bifenililazetidin-2-onas fenólicas
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006249905A1 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2006138163A2 (fr) * 2005-06-15 2006-12-28 Merck & Co., Inc. Composes anti-hypercholesterolemiques
ATE450526T1 (de) * 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
CA2613239A1 (fr) * 2005-06-22 2006-12-28 Manne Satyanarayana Reddy Procede ameliore pour la preparation d'ezetimibe
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1741427A1 (fr) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant la simvastatin et l'ezetimibe
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
US20070259845A1 (en) * 2005-09-08 2007-11-08 Kansal Vinod K Processes for the preparation of (3R,4S)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
HUP0501164A2 (en) * 2005-12-20 2007-07-30 Richter Gedeon Nyrt New industrial process for the production of ezetimibe
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
DE602006009845D1 (de) * 2005-12-22 2009-11-26 Medichem Sa Verfahren zur herstellung von zwischenprodukten für die herstellung von ezetimibe
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
CA2642388C (fr) * 2006-02-16 2013-11-05 Kotobuki Pharmaceutical Co., Ltd. Methode de synthese d'un alcool optiquement actif
EP1986489A2 (fr) 2006-02-24 2008-11-05 Schering Corporation Orthologues de npc1l1
MX2008011418A (es) * 2006-03-06 2008-09-22 Teva Pharma Composiciones de ezetimibe.
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
EP2004639A2 (fr) * 2006-04-10 2008-12-24 Teva Pharmaceutical Industries Ltd Procédés de synthèse de l'azétidinone
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
CN101494980A (zh) * 2006-07-14 2009-07-29 兰贝克赛实验室有限公司 HMG-CoA还原酶抑制剂的多晶型形式及其应用
EP1937636A1 (fr) * 2006-08-29 2008-07-02 Teva Pharmaceutical Industries Ltd. Procédés de purification de la (3r,4s)-4-(4-hydroxy-protégé-phényl)-1-(4-fluorophényl)-3-(4-fluorophényl)-3-oxopropyl¨azétidin-2-one
CA2661404A1 (fr) * 2006-09-05 2008-03-13 Schering Corporation Compositions pharmaceutiques pour un traitement des lipides et dans le traitement de l'atherosclerose et de la steatose hepatique
EP2091534A1 (fr) * 2006-09-15 2009-08-26 Schering Corporation Dérivés d'azétidinone et procédés d'utilisation de ceux-ci
WO2008033464A2 (fr) * 2006-09-15 2008-03-20 Schering Corporation Dérivés d'azétidinone et procédés d'utilisation de ceux-ci
CA2663434A1 (fr) * 2006-09-15 2008-03-20 Schering Corporation Derives d'azetidinone spirocyclique traitant les troubles du metabolisme des lipides, la douleur, le diabete et d'autres troubles
KR20090071589A (ko) 2006-09-15 2009-07-01 쉐링 코포레이션 통증 및 지질 대사 장애의 치료에 유용한 아제티딘 및 아제티돈 유도체
CA2663500A1 (fr) * 2006-09-15 2008-03-20 Schering Corporation Derives d'azetidine spiro-condenses convenant pour le traitement de la douleur, du diabete et des troubles du metabolisme des lipides
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
CN100564357C (zh) * 2006-10-20 2009-12-02 浙江天宇药业有限公司 一种氮杂环丁酮衍生物及其合成方法
CA2672221A1 (fr) * 2006-12-20 2008-07-17 Merck & Co., Inc. Compose anti-hypercholesterolemique
EP1939174A1 (fr) * 2006-12-21 2008-07-02 LEK Pharmaceuticals D.D. Complexe d'inclusion d'ezetimibe et une cyclodextrine et procédés pour son préparation
AU2007338625A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
CN101679236B (zh) * 2007-01-24 2013-03-06 克尔克公司 依泽替米贝的制备方法和其的衍生物
WO2008096372A2 (fr) * 2007-02-06 2008-08-14 Ind-Swift Laboratories Limited Procédé de préparation de l'ézétimibe extrêmement pur au moyen de nouveaux intermédiaires
WO2008104875A1 (fr) * 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones comme inhibiteurs d'absorption de cholestérol
JPWO2008108486A1 (ja) 2007-03-06 2010-06-17 帝人ファーマ株式会社 １−ビアリールアゼチジノン誘導体
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
WO2008123953A1 (fr) * 2007-04-02 2008-10-16 Merck & Co., Inc. Composé anti-hypercholestérolémique
WO2008130616A2 (fr) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines comme modulateurs des récepteurs cb1
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
JP2010529148A (ja) * 2007-06-07 2010-08-26 テバ ファーマシューティカル インダストリーズ リミティド エゼチミブ製造のための還元方法
US20080318920A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched ezetimibe
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
WO2009005671A2 (fr) * 2007-06-28 2009-01-08 Schering Corporation Pipérazines à substitution servant d'antagonistes des récepteurs cb1
EP2548874A3 (fr) * 2007-06-28 2013-05-15 Intervet International B.V. Pipérazines substituées utilisées en tant qu'antagonistes CB1
CA2694378A1 (fr) * 2007-07-27 2009-02-05 Cipla Limited Compositions pharmaceutiques et leur procede de preparation
WO2009024889A2 (fr) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
WO2009032264A1 (fr) * 2007-08-30 2009-03-12 Teva Pharmaceutical Industries Ltd. Procédés de préparation d'intermédiaires d'ézétimibe par réduction microbienne
WO2009027785A2 (fr) * 2007-08-30 2009-03-05 Pfizer Products Inc. Composés pharmaceutiques et dérivés
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UA103179C2 (ru) * 2007-12-10 2013-09-25 Ратиофарм Гмбх Фармацевтическая композиция, которая содержит эзетимиб
CZ305066B6 (cs) * 2008-02-25 2015-04-22 Zentiva, K.S. Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
EP2128133A1 (fr) 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Procédé et composition d'ézétimibe
US20110077232A1 (en) * 2008-06-06 2011-03-31 Nicox S.A. Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
EP2329014B1 (fr) 2008-08-29 2014-10-22 Codexis, Inc. Polypeptides de cetoreductase pour la production stéréosélective de (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
EP2355812B1 (fr) 2008-11-14 2019-07-10 Bomi P. Framroze Diminuer le taux circulant du complexe lipoprotéine de basse densité oxydée/bêta-2-glycoprotéine 1 pour le traitement de l'athérosclérose
EP2204170A1 (fr) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Composition pharmaceutique comprenant ézétimide et simvastatine
WO2010075069A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2216016A1 (fr) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
WO2010100255A1 (fr) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Compositions pharmaceutiques hypocholestérolémiques
PL2229938T3 (pl) 2009-03-13 2012-09-28 Sanovel Ilac Sanayi Ve Ticaret As Kompozycje ezetymibu
WO2010113182A1 (fr) 2009-03-31 2010-10-07 Lupin Limited Intermediaires utilises dans la preparation de 1,4-diphenylazetidinone
EP2414529A2 (fr) 2009-04-01 2012-02-08 Matrix Laboratories Ltd Procédé enzymatique pour la préparation de la (s)-5-(4-fluorophényl)-5-hydroxy-1-morpholin-4-yl-pentan-1-one, un intermédiaire de l'ézétimibe et la conversion ultérieure en ézétimibe
EP2448919A2 (fr) 2009-07-02 2012-05-09 Mahmut Bilgic Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
WO2011002424A2 (fr) 2009-07-02 2011-01-06 Bilgic Mahmut Préparation pharmaceutique améliorant la solubilité et la stabilité
WO2011002422A2 (fr) 2009-07-02 2011-01-06 Bilgic Mahmut Formulation pharmaceutique améliorant la solubilité
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
SG178456A1 (en) 2009-08-19 2012-04-27 Codexis Inc Ketoreductase polypeptides for the preparation of phenylephrine
EP2539389B1 (fr) 2010-02-24 2017-12-20 Relypsa, Inc. Polymères d'amine pour l'utilisation comme séquestrants de l'acide biliaire
JP5865847B2 (ja) 2010-02-24 2016-02-17 レリプサ， インコーポレイテッド 胆汁酸捕捉剤として使用するための架橋されたポリビニルアミン、ポリアリルアミンおよびポリエチレンイミン
BR112012021448A2 (pt) 2010-02-24 2016-05-31 Relypsa Inc polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina.
EP2368543A1 (fr) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Procédé de préparation de composition pharmaceutique granulée comprenant de la simvastatine et/ou ézétimibe
DK2561069T3 (en) 2010-04-23 2017-05-01 Alexion Pharma Inc Enzyme for lysosomal storage disease
WO2011140219A1 (fr) 2010-05-04 2011-11-10 Codexis, Inc. Biocatalyseurs pour la synthèse d'ézétimibe
ES2372460B1 (es) 2010-07-09 2012-11-16 Moehs Ibérica S.L. Nuevo método para la preparación de ezetimiba.
NZ608292A (en) 2010-09-09 2014-10-31 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
LT3400944T (lt) 2010-11-04 2020-09-25 Albireo Ab Ibat inhibitoriai, skirt kepenų ligų gydymui
BR112013010705B1 (pt) 2010-11-08 2020-11-17 Albireo Ab uso de um inibidor de ibat e um coagulante de ácido biliar, e formulação farmacêutica
WO2012076030A1 (fr) 2010-12-10 2012-06-14 Pharmathen S.A. Procédé de préparation de composés intermédiaires utiles dans la préparation de l'ézétimibe
WO2012112681A1 (fr) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Procédés de traitement d'un déficit en lipase acide lysosomale
US8455474B2 (en) 2011-03-04 2013-06-04 Mackay Memorial Hospital Method for treating tuberculosis
WO2012155932A1 (fr) 2011-05-17 2012-11-22 Pharmathen S.A. Procédé amélioré pour la préparation d'ézétimibe
PL231215B1 (pl) 2011-06-15 2019-02-28 Inst Chemii Organicznej Polskiej Akademii Nauk Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
CN102675177A (zh) * 2011-06-28 2012-09-19 常州制药厂有限公司 一种降血脂药物及其关键中间体的制备方法
CN102952055A (zh) * 2011-08-16 2013-03-06 凯瑞斯德生化(苏州)有限公司 一种依泽替米贝和其中间体的制备方法
CN103204795B (zh) * 2012-01-11 2016-12-14 重庆华邦胜凯制药有限公司 一种手性氮杂环丁酮类化合物的制备方法
WO2013166117A1 (fr) 2012-05-01 2013-11-07 Althera Life Sciences, Llc Formulation de comprimé oral constituée d'une combinaison fixe de rosuvastatine et d'ézétimibe pour le traitement de l'hyperlipidémie et de maladies cardiovasculaires
CN103570574B (zh) 2012-07-20 2016-04-13 中国科学院上海有机化学研究所 一种依泽替米贝的合成方法及该方法中所用的中间体
CN103102297A (zh) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 一种新的依折麦布的合成方法
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
CN103864708A (zh) * 2012-12-12 2014-06-18 天津市医药集团技术发展有限公司 一种依折麦布中间体的制备方法
WO2015039675A1 (fr) 2013-09-23 2015-03-26 Pharmathen S.A. Nouveau procédé de préparation d'intermédiaires d'ézétimibe
WO2015066252A1 (fr) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Composés antagonistes du récepteur du glucagon, compositions correspodantes et méthodes d'utilisation
WO2015092448A1 (fr) 2013-12-18 2015-06-25 Rudjer Boskovic Institute Inhibiteurs de l'absorption du cholestérol de type bêta-lactamines
CN103739537B (zh) * 2013-12-24 2015-05-20 连云港恒运医药科技有限公司 依折麦布的新合成方法
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN103755616A (zh) * 2013-12-31 2014-04-30 北京万全德众医药生物技术有限公司 一种制备依泽替米贝异构体的方法
JP6649902B2 (ja) 2014-05-30 2020-02-19 ファイザー・インク 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
CN105294426B (zh) * 2014-06-09 2019-05-14 浙江海正药业股份有限公司 氮杂环丁酮化合物制备方法及其中间体
CN104447474A (zh) * 2014-11-11 2015-03-25 武汉武药科技有限公司 一种依折麦布异构体的合成方法
CN104387308A (zh) * 2014-11-18 2015-03-04 武汉福星生物药业有限公司 一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
JP2016145173A (ja) * 2015-02-09 2016-08-12 株式会社トクヤマ （３ｒ，４ｓ）‐１‐（４‐フルオロフェニル）‐［３（ｓ）‐ヒドロキシ‐３‐（４‐フルオロフェニル）プロピル］‐（４‐ヒドロキシフェニル）‐２‐アゼチジノンの製造方法
KR102370582B1 (ko) 2015-03-13 2022-03-04 에스페리온 테라피유틱스 인코포레이티드 Ｅｔｃ1002 및 에제티미브를 포함하는 고정 용량 조합 및 제형 및 심혈관 질환의 치료 또는 이의 위험의 감소 방법
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN105287513A (zh) * 2015-10-23 2016-02-03 浙江永宁药业股份有限公司 一种依折麦布药物组合物及其制备方法
CN107098841A (zh) * 2016-02-19 2017-08-29 常州方楠医药技术有限公司 一种依折麦布的制备方法及该方法中所用的中间体
WO2018103642A1 (fr) 2016-12-05 2018-06-14 Patsnap Systèmes, appareils et procédés de recherche et d'affichage d'informations disponibles dans de grandes bases de données selon la similarité de structures chimiques discutées dans celles-ci
US20180338922A1 (en) 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
EP3437636A1 (fr) 2017-08-02 2019-02-06 Adamed sp. z o.o. Composition pharmaceutique comprenant de l'ézétimibe
CA3087281A1 (fr) 2018-01-16 2019-07-25 Q.E.D. Environmental Systems, Inc. Systeme de surveillance de niveau de fluide et procede incorporant un systeme de capteur de pression ayant un sac gonflable/repliable
CN113825839A (zh) 2019-03-20 2021-12-21 雷杰纳荣制药公司 用固醇调节元件结合蛋白切割激活蛋白(scap)抑制剂治疗脂质水平升高
CA3133000A1 (fr) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Traitement de niveaux de lipides accrus avec des inhibiteurs du facteur de transcription 1 de liaison a un element regulateur de sterol (srebf1)
WO2021019499A1 (fr) 2019-07-31 2021-02-04 TECNIMEDE - Sociedade Técnico-medicinal, SA Compositions solides orales à libération immédiate à unités multiples, procédés et utilisations de celles-ci
EP4188338A1 (fr) 2020-07-27 2023-06-07 KRKA, d.d., Novo mesto Comprimé bicouche comprenant de l'ézétimibe et de l'atorvastatine
EP4188372A1 (fr) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapide destiné à être utilisé dans des méthodes de traitement de l'hyperlipidémie et de l'hypercholestérolémie chez des patients pédiatriques
EP4357333A4 (fr) * 2021-06-17 2025-08-27 Zhejiang Hisun Pharm Co Ltd Intermédiaire d'hystéétimibe et son procédé de préparation
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes
WO2024151311A1 (fr) 2023-01-09 2024-07-18 Esperion Therapeutics, Inc. Méthodes de traitement utilisant de l'acide bempédoïque
US20250075216A1 (en) 2023-08-29 2025-03-06 Regeneron Pharmaceuticals, Inc. Treatment Of Muscle Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) Inhibitors
EP4566591A1 (fr) 2023-12-07 2025-06-11 KRKA, d.d., Novo mesto Forme pharmaceutique solide comprenant de l'ézétimibe et de la pitavastatine

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (de) 1970-09-23 1972-03-30 Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt Neue Azetidinone-(2) und Verfahren zu deren Herstellung
CA1063108A (fr) 1973-12-28 1979-09-25 Fujisawa, Pharmaceutical Co. Derives de l'azetidinone et procede de preparation
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4144232A (en) 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4500456A (en) 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
IL65158A0 (en) 1981-03-09 1982-05-31 Lilly Co Eli Azetidinones
US4784734A (en) 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4443372A (en) 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
GR81665B (fr) 1983-02-02 1984-12-12 Univ Notre Dame Du Lac
US4675399A (en) 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
US4565654A (en) 1983-03-28 1986-01-21 University Of Notre Dame Du Lac N-Acyloxy monocyclic β-lactams
WO1985004876A1 (fr) 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. Derives de 2-azetidinone et leur procede de preparation
US4576749A (en) 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229381A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
WO1985003707A1 (fr) 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BD PYRIDINE ET SES SELS, LEURS PROCEDES DE PRODUCTION ET COMPOSITIONS PHARMACEUTIQUES CONTENANT SES COMPOSES
US4581170A (en) 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
CA1268780A (fr) 1984-08-03 1990-05-08 Richard H. Mueller Groupes protecteurs n-hydroxyles et methode de preparation de 3-acylamino-1-hydroxy-2-azetidinones
US4633017A (en) 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4620867A (en) 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
EP0282492A1 (fr) 1986-01-23 1988-09-21 The Upjohn Company N-acyl-2-azetidinones antimicrobiennes
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
USRE36481E (en) 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4803266A (en) 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
US4806564A (en) 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4816477A (en) 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US4834846A (en) 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
EP0333268A1 (fr) 1988-03-18 1989-09-20 Merck & Co. Inc. Procédé pour la synthèse d'une 3-bêta-hydrogène (3R) 4-aroyloxy azétidinone chirale
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
JPH0645656B2 (ja) 1988-06-16 1994-06-15 出光石油化学株式会社 スチレン系共重合体およびその製造方法
US4952689A (en) 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
FR2640621B1 (fr) 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
CA2016467A1 (fr) 1989-06-05 1990-12-05 Martin Eisman Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
JPH03108490A (ja) * 1989-06-30 1991-05-08 Shionogi & Co Ltd フォスフォリパーゼａ↓２阻害物質
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
IL99658A0 (en) 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
EP0508425A1 (fr) 1991-04-12 1992-10-14 Schering Corporation Amides bicycliques inhibiteurs de l'acyl-coenzyme A, cholestérol acyltransférase
US5124337A (en) 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
GB2264707A (en) 1991-06-18 1993-09-08 Roger Michael Marchbanks Acridine derivatives for treating alzheimer's disease
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993000332A1 (fr) 1991-06-25 1993-01-07 Merck & Co., Inc. Azetidinones substituees utilisees comme agents antiinflammatoires et antidegeneratifs
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
CA2114007C (fr) 1991-07-23 2005-12-20 Duane A. Burnett Composes beta-lactame substitues utilises comme agents hypocholesterolemiants et procedes pour leur preparation
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
ATE158789T1 (de) 1991-07-23 1997-10-15 Schering Corp Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung
JP2620437B2 (ja) * 1991-09-27 1997-06-11 宇部興産株式会社 ω−ヒドロキシ−（ω−３）−ケトニトリルおよびω−ヒドロキシ脂肪酸の製法
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
US5321031A (en) 1992-09-23 1994-06-14 Schering Corporation 1,2-disubstituted ethyl amides as inhibitors of ACAT
US5631363A (en) 1992-11-13 1997-05-20 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
AU3494093A (en) 1993-01-22 1994-08-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
CN1118600A (zh) 1993-02-26 1996-03-13 先灵公司 2-苄基-多环鸟嘌呤衍生物以及制备它们的方法
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
WO1995001961A1 (fr) 1993-07-09 1995-01-19 Schering Corporation Procede de synthese d'azetidinones
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
GB9406074D0 (en) 1994-03-26 1994-05-18 Glaxo Spa Chemical process
US5576470A (en) 1994-08-29 1996-11-19 Henkel Corporation Polyol esters of ether carboxylic acids and fiber finishing methods
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
WO1997016424A1 (fr) 1995-11-02 1997-05-09 Schering Corporation Procede de preparation de 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl ou 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
EP0855396A1 (fr) 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Métabolites de l'acide thioctique et leur utilisation
CA2318959A1 (fr) 1998-02-20 1999-08-26 Avmax, Inc. Compose d'epimorphine et utilisation de ce dernier
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
AU780624B2 (en) 1999-11-04 2005-04-07 Andrx Corporation Method of treating amyloid beta precursor disorders
DE60121557T2 (de) 2000-04-07 2007-07-12 Pfizer Products Inc., Groton Metabolite von estrogen-agonisten/-antagonisten
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
CA2172149C (fr) 2000-11-28
NO961133D0 (no) 1996-03-20
CZ288891B6 (cs) 2001-09-12
NL300132I2 (nl) 2003-11-03
FR05C0040I1 (fr) 2005-10-28
DE69418613D1 (de) 1999-06-24
ZA947086B (en) 1995-03-14
US5767115A (en) 1998-06-16
NO305902B1 (no) 1999-08-16
JPH08509989A (ja) 1996-10-22
CN1131416A (zh) 1996-09-18
LU92544I2 (fr) 2015-01-20
NZ274041A (en) 1997-12-19
MY111314A (en) 1999-10-30
DE69418613T2 (de) 1999-09-30
US5846966A (en) 1998-12-08
GEP20043149B (en) 2004-01-12
NO2005003I1 (no) 2005-02-28
LU91050I2 (fr) 2004-10-12
BE2014C056I2 (en) 2018-02-05
NL300132I1 (nl) 2003-10-01
AU681445C (en) 2004-07-08
FR05C0040I2 (fr) 2006-12-29
EP0720599B1 (fr) 1999-05-19
RU2138480C1 (ru) 1999-09-27
LU91160I2 (fr) 2005-11-25
KR960704842A (ko) 1996-10-09
IL110956A (en) 2001-01-11
NO2017042I1 (no) 2017-08-02
ES2132432T3 (es) 1999-08-16
SG46208A1 (en) 1998-02-20
FI110321B (fi) 2002-12-31
NL300172I1 (nl) 2005-04-01
SK35596A3 (en) 1997-02-05
FI961300A7 (fi) 1996-03-21
USRE42461E1 (en) 2011-06-14
ATE180249T1 (de) 1999-06-15
NO961133L (no) 1996-03-20
PL182617B1 (pl) 2002-02-28
UA41948C2 (uk) 2001-10-15
BR1100159A (pt) 2006-09-26
TW427974B (en) 2001-04-01
DK0720599T3 (da) 1999-11-08
NL300172I2 (nl) 2005-08-01
PL313589A1 (en) 1996-07-08
TNSN94094A1 (fr) 1995-04-25
HU221185B1 (en) 2002-08-28
MA23332A1 (fr) 1995-04-01
HUT73852A (en) 1996-09-30
HU9600697D0 (en) 1996-05-28
DE122004000026I1 (de) 2004-11-18
US5631365A (en) 1997-05-20
EP0720599A1 (fr) 1996-07-10
USRE37721E1 (en) 2002-05-28
DE10399001I1 (de) 2003-06-12
NO2014023I1 (no) 2014-09-12
CZ83996A3 (en) 1996-08-14
GR3030312T3 (en) 1999-09-30
DE10399001I2 (de) 2012-05-16
WO1995008532A1 (fr) 1995-03-30
FI961300A0 (fi) 1996-03-21
CZ288861B6 (cs) 2001-09-12
NO2005003I2 (no) 2005-10-03
SK281067B6 (sk) 2000-11-07
JP2803908B2 (ja) 1998-09-24
FR14C0068I1 (fr) 2014-10-17
KR100186853B1 (ko) 1999-05-01
NO2014022I1 (no) 2014-09-10
CN1050830C (zh) 2000-03-29
NO2003007I2 (no) 2005-08-29
IL110956A0 (en) 1994-11-28
AU681445B2 (en) 1997-08-28
DE122004000026I2 (de) 2005-09-29
AU7795294A (en) 1995-04-10

Similar Documents

Publication Publication Date Title
LU92545I2 (fr) Ezetimibe en combinaison avec atorvastatine ou leurs sels pharmaceutiquement acceptées, y compris atorvastatine sous forme d'atorvastatine calcique trihydratée
AR026605A1 (es) Un derivado de 6-mercapto-ciclodextrina, su uso, una composicion farmaceutica que lo comprende, un kit para proporcionar bloqueo neuromuscular y sureversion, y un metodo para la reversion del bloqueo neuromuscular inducido por farmacos
SE9604786D0 (sv) New compounds
DE3575130D1 (de) Antiinflammatorische 1,n-diarylpyrazol-3-amine, deren zusammensetzungen und verfahren zu deren herstellung.
PT768086E (pt) Tratamento de tinido utilizando agentes neuroprotectores
ATE137749T1 (de) Benzomorphane und ihre verwendung als arzneimittel
FI930171A0 (fi) Piperidinfoereningar, framstaellning och anvaendning av dessa
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE69330601D1 (de) Serotoninergische ergolin derivate
FI932650A7 (fi) B-solujen maligniteettien hoitoon tarkoitetut farmaseuttiset seokset
KR890701588A (ko) 치료학적으로 유용한 β-락탐